Comparative Analysis of Antimicrobial Antibodies between Mild and Severe COVID-19.
Comparative Analysis of Antimicrobial Antibodies between Mild and Severe COVID-19.
复制标题
DOI：
10.1128/spectrum.04690-22
复制
发表时间：
2023-08-17
影响因子：
3.7
通讯作者：
中科院分区：
文献类型：
--
作者：
2019冠状病毒病（COVID-19）患者表现出广泛的临床表现。一个人的抗微生物抗体谱，部分由过去的感染或疫苗接种形成，可以反映免疫系统的健康，这对控制和解决感染至关重要。我们进行了探索性的免疫蛋白质组学研究，使用微生物蛋白阵列显示318全长抗原从77种病毒和3种细菌。我们比较了来自墨西哥和意大利的3个独立队列中135名轻度COVID-19疾病患者和215名重度疾病患者的抗菌抗体谱。重症患者年龄较大，合并症患病率较高。我们证实，重症患者引发了更强的抗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的反应。我们发现，在患有严重疾病的患者中，针对HCoV-229 E和HcoV-NL 63的抗体也较高，但不针对HcoV-HKU 1和HcoV-OC 43。我们发现，对于一组针对冠状病毒、疱疹病毒和其他呼吸道病毒的IgG和伊加抗体，在所有三个队列中，具有最高反应水平的患者亚组的严重疾病发生率高于轻度疾病。相反，在所有3个队列中，较少的抗体在轻度疾病中显示出一致的较高患病率。COVID-19的临床表现从无症状到可能导致重症监护甚至死亡的危重疾病不等。免疫系统的健康，部分由过去的感染或疫苗接种所塑造，对于控制和解决感染至关重要。使用创新的蛋白质阵列平台，我们调查了来自不同地理区域的轻度或重度COVID-19患者中80种不同病毒和细菌的数百种全长微生物抗原的抗体。我们不仅证实了严重的COVID-19疾病与SARS-CoV-2抗体反应的较高反应性之间的关联，而且还发现了与疱疹病毒和其他呼吸道病毒抗体反应的已知和新关联。我们的研究代表着在理解导致COVID-19疾病严重程度的因素方面迈出了重要一步。我们还证明了全面的抗微生物抗体谱分析在解读严重COVID-19风险因素方面的作用。我们预计，我们的方法将在传染病中有广泛的应用。
Patients with 2019 coronavirus disease (COVID-19) exhibit a broad spectrum of clinical presentations. A person’s antimicrobial antibody profile, as partially shaped by past infection or vaccination, can reflect the immune system health that is critical to control and resolve the infection. We performed an explorative immunoproteomics study using microbial protein arrays displaying 318 full-length antigens from 77 viruses and 3 bacteria. We compared antimicrobial antibody profiles between 135 patients with mild COVID-19 disease and 215 patients with severe disease in 3 independent cohorts from Mexico and Italy. Severe disease patients were older with higher prevalence of comorbidities. We confirmed that severe disease patients elicited a stronger anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) response. We showed that antibodies against HCoV-229E and HcoV-NL63 but not against HcoV-HKU1 and HcoV-OC43 were also higher in those who had severe disease. We revealed that for a set of IgG and IgA antibodies targeting coronaviruses, herpesviruses, and other respiratory viruses, a subgroup of patients with the highest reactivity levels had a greater incidence of severe disease compared to those with mild disease across all three cohorts. On the contrary, fewer antibodies showed consistent greater prevalence in mild disease in all 3 cohorts. IMPORTANCE The clinical presentations of COVID-19 range from asymptomatic to critical illness that may lead to intensive care or even death. The health of the immune system, as partially shaped by past infections or vaccinations, is critical to control and resolve the infection. Using an innovative protein array platform, we surveyed antibodies against hundreds of full-length microbial antigens from 80 different viruses and bacteria in COVID-19 patients from different geographic regions with mild or severe disease. We not only confirmed the association of severe COVID-19 disease with higher reactivity of antibody responses to SARS-CoV-2 but also uncovered known and novel associations with antibody responses against herpesviruses and other respiratory viruses. Our study represents a significant step forward in understanding the factors contributing to COVID-19 disease severity. We also demonstrate the power of comprehensive antimicrobial antibody profiling in deciphering risk factors for severe COVID-19. We anticipate that our approach will have broad applications in infectious diseases.
登录
查看更多内容
影响因子：
3.5
作者：
Saade A;Moratelli G;Azoulay E;Darmon M
通讯作者：
Darmon M
影响因子：
17.1
作者：
Lastwika, Kristin J.;Kunihiro, Andrew;Solan, Joell L.;Zhang, Yuzheng;Taverne, Lydia R.;Shelley, David;Rho, Jung-Hyun;Randolph, Timothy W.;Li, Christopher I.;Grogan, Eric L.;Massion, Pierre P.;Fitzpatrick, Annette L.;MacPherson, David;Houghton, A. McGarry;Lampe, Paul D.
通讯作者：
Lampe, Paul D.
危及生命的Covid-19患者中针对I型IFN的自身抗体。
DOI：
10.1126/science.abd4585
发表时间：
2020-10-23
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Bastard P;Rosen LB;Zhang Q;Michailidis E;Hoffmann HH;Zhang Y;Dorgham K;Philippot Q;Rosain J;Béziat V;Manry J;Shaw E;Haljasmägi L;Peterson P;Lorenzo L;Bizien L;Trouillet-Assant S;Dobbs K;de Jesus AA;Belot A;Kallaste A;Catherinot E;Tandjaoui-Lambiotte Y;Le Pen J;Kerner G;Bigio B;Seeleuthner Y;Yang R;Bolze A;Spaan AN;Delmonte OM;Abers MS;Aiuti A;Casari G;Lampasona V;Piemonti L;Ciceri F;Bilguvar K;Lifton RP;Vasse M;Smadja DM;Migaud M;Hadjadj J;Terrier B;Duffy D;Quintana-Murci L;van de Beek D;Roussel L;Vinh DC;Tangye SG;Haerynck F;Dalmau D;Martinez-Picado J;Brodin P;Nussenzweig MC;Boisson-Dupuis S;Rodríguez-Gallego C;Vogt G;Mogensen TH;Oler AJ;Gu J;Burbelo PD;Cohen JI;Biondi A;Bettini LR;D'Angio M;Bonfanti P;Rossignol P;Mayaux J;Rieux-Laucat F;Husebye ES;Fusco F;Ursini MV;Imberti L;Sottini A;Paghera S;Quiros-Roldan E;Rossi C;Castagnoli R;Montagna D;Licari A;Marseglia GL;Duval X;Ghosn J;HGID Lab;NIAID-USUHS Immune Response to COVID Group;COVID Clinicians;COVID-STORM Clinicians;Imagine COVID Group;French COVID Cohort Study Group;Milieu Intérieur Consortium;CoV-Contact Cohort;Amsterdam UMC Covid-19 Biobank;COVID Human Genetic Effort;Tsang JS;Goldbach-Mansky R;Kisand K;Lionakis MS;Puel A;Zhang SY;Holland SM;Gorochov G;Jouanguy E;Rice CM;Cobat A;Notarangelo LD;Abel L;Su HC;Casanova JL
通讯作者：
Casanova JL
影响因子：
15.9
作者：
Dangi, Tanushree;Palacio, Nicole;Penaloza-MacMaster, Pablo
通讯作者：
Penaloza-MacMaster, Pablo
影响因子：
1.9
作者：
Pepe, MS;Longton, G;Schummer, M
通讯作者：
Schummer, M